Literature DB >> 22775069

Risk: benefit of treating high blood pressure in older adults.

Omar Mukhtar1, Stephen H D Jackson.   

Abstract

Older people (those aged 65 years or over) comprise over 15% of the UK's population and this cohort is growing. Whilst at greatest risk from systemic arterial hypertension (hypertension), its resultant end organ damage and clinically significant cardiovascular disease, this group was initially neglected in clinical trials and thereby denied treatment, with the lack of evidence cited as justification. However since the 1960s, when the first landmark trials in severe diastolic hypertension were published, there has been a progressive attempt to understand the pathophysiology of hypertension and to expand the evidence base for treatment in older adults. In contrast to the participants of the very first randomized trials who had a mean age of 51 years, the recent Hypertension in the Very Elderly Trial demonstrated significant mortality and morbidity benefits from the treatment of both mixed systolic and diastolic hypertension, as well as isolated systolic hypertension in octogenarians. This review highlights the progressive evidence base behind the relative risks and benefits of treating hypertension in older adults.
© 2012 The Authors. British Journal of Clinical Pharmacology © 2012 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 22775069      PMCID: PMC3555045          DOI: 10.1111/j.1365-2125.2012.04375.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  36 in total

Review 1.  Evolution and modulation of age-related medial elastocalcinosis: impact on large artery stiffness and isolated systolic hypertension.

Authors:  Huy Hao Dao; Rachida Essalihi; Céline Bouvet; Pierre Moreau
Journal:  Cardiovasc Res       Date:  2005-05-01       Impact factor: 10.787

2.  Blood pressure and the global burden of disease 2000. Part 1: estimates of blood pressure levels.

Authors:  Carlene M M Lawes; Stephen Vander Hoorn; Malcolm R Law; Paul Elliott; Stephen MacMahon; Anthony Rodgers
Journal:  J Hypertens       Date:  2006-03       Impact factor: 4.844

3.  Treatment of hypertension in the elderly.

Authors:  Stella Douma; Konstantinos Petidis; Chrysanthos Zamboulis
Journal:  N Engl J Med       Date:  2008-08-28       Impact factor: 91.245

4.  Prevention of dementia: Syst-Eur trial.

Authors:  G Zuccalà; C Pedone; A Cocchi; R Bernabei; P Carbonin
Journal:  Lancet       Date:  1999-01-16       Impact factor: 79.321

5.  Prevention of dementia: Syst-Eur trial.

Authors:  D Leys; F Pasquier
Journal:  Lancet       Date:  1999-01-16       Impact factor: 79.321

6.  Changes in antihypertensive therapy--the role of adverse effects and compliance.

Authors:  R Düsing; B Weisser; T Mengden; H Vetter
Journal:  Blood Press       Date:  1998-11       Impact factor: 2.835

7.  Orthostatic hypotension predicts mortality in elderly men: the Honolulu Heart Program.

Authors:  K H Masaki; I J Schatz; C M Burchfiel; D S Sharp; D Chiu; D Foley; J D Curb
Journal:  Circulation       Date:  1998-11-24       Impact factor: 29.690

8.  Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial.

Authors:  F Forette; M L Seux; J A Staessen; L Thijs; W H Birkenhäger; M R Babarskiene; S Babeanu; A Bossini; B Gil-Extremera; X Girerd; T Laks; E Lilov; V Moisseyev; J Tuomilehto; H Vanhanen; J Webster; Y Yodfat; R Fagard
Journal:  Lancet       Date:  1998-10-24       Impact factor: 79.321

9.  Treatment of hypertension in patients 80 years of age or older.

Authors:  Nigel S Beckett; Ruth Peters; Astrid E Fletcher; Jan A Staessen; Lisheng Liu; Dan Dumitrascu; Vassil Stoyanovsky; Riitta L Antikainen; Yuri Nikitin; Craig Anderson; Alli Belhani; Françoise Forette; Chakravarthi Rajkumar; Lutgarde Thijs; Winston Banya; Christopher J Bulpitt
Journal:  N Engl J Med       Date:  2008-03-31       Impact factor: 91.245

Review 10.  Mechanical factors in arterial aging: a clinical perspective.

Authors:  Michael F O'Rourke; Junichiro Hashimoto
Journal:  J Am Coll Cardiol       Date:  2007-06-18       Impact factor: 24.094

View more
  3 in total

1.  The impact of age on the benefits and risks of aliskiren treatment: analyses of the 3A registry.

Authors:  S Friedrich; U Zeymer; R Dechend; I Hagedorn; T Riemer; C Zemmrich; P Bramlage; D Pittrow; J Senges; R E Schmieder
Journal:  J Hum Hypertens       Date:  2014-10-02       Impact factor: 3.012

Review 2.  The Hypertension in the Very Elderly Trial - latest data.

Authors:  Omar Mukhtar; Stephen H D Jackson
Journal:  Br J Clin Pharmacol       Date:  2013-04       Impact factor: 4.335

3.  Effect of Strength Training on Oxidative Stress and the Correlation of the Same with Forearm Vasodilatation and Blood Pressure of Hypertensive Elderly Women: A Randomized Clinical Trial.

Authors:  Filipe Fernandes Oliveira Dantas; Maria do Socorro Brasileiro-Santos; Rafael Marinho Falcão Batista; Leone Severino do Nascimento; Lúcio Roberto Cançado Castellano; Raphael Mendes Ritti-Dias; Kenio Costa Lima; Amilton da Cruz Santos
Journal:  PLoS One       Date:  2016-08-16       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.